Johnson & Johnson reported a 1.7 percent rise in fourth-quarter sales, due to a strong demand for its newer products.
The diversified healthcare company’s sales rose to $18.11 billion in the fourth quarter from $17.81 billion a year earlier.
Net earnings rose to $3.81 billion, or $1.38 per share, from $3.22 billion, or $1.15 per share.
The band-aid maker also said on Tuesday that it was looking to divest its diabetes care division.
By Natalie Grover
Source: Reuters
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
